Eloxx Pharmaceuticals (NASDAQ:ELOX) Stock Gets Price Target Trim from Guggenheim

Eloxx Pharmaceuticals (NASDAQ:ELOX) had its price target lowered by Guggenheim from $43.00 to $40.00 in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

ELOX has been the topic of a number of other research reports. Weiss Ratings assumed coverage on Eloxx Pharmaceuticals in a research note on Friday, August 14th. They issued a “sell (d)” rating on the stock. Cantor Fitzgerald started coverage on shares of Eloxx Pharmaceuticals in a report on Thursday, October 15th. They issued an “overweight” rating for the company. Lifesci Capital started coverage on shares of Eloxx Pharmaceuticals in a research report on Wednesday, July 22nd. They issued an “outperform” rating and a $40.00 target price on the stock. Leerink Partners set a $32.00 price target on shares of Eloxx Pharmaceuticals and gave the company an “outperform” rating in a research report on Friday, September 18th. Finally, Zacks Research raised shares of Eloxx Pharmaceuticals to a “hold” rating in a research note on Friday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Eloxx Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $37.33.

Eloxx Pharmaceuticals Stock Up 1.9%

NASDAQ:ELOX opened at $13.45 on Wednesday. The stock has a 50 day moving average of $15.34 and a 200-day moving average of $13.65. Eloxx Pharmaceuticals has a 52 week low of $8.20 and a 52 week high of $23.40.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last released its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter. As a group, sell-side analysts anticipate that Eloxx Pharmaceuticals will post -2.61 earnings per share for the current fiscal year.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc was a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases caused by nonsense mutations. Its research centered on ribosome modulation therapy, an approach intended to encourage cells to read through certain genetic mutations and restore production of functional proteins.

The company’s lead investigational product was ELX-02, a synthetic aminoglycoside designed to promote readthrough of nonsense mutations while seeking to limit the toxicity associated with older aminoglycoside compounds.